Science & Medicine

MMP-9 and Crohn’s Disease

Crohn’s disease (CD) is a relapsing/remitting inflammatory disease of the gastrointestinal mucosa. Although currently prescribed medicines exhibit some efficacy, the quality of life of treated CD patients is poor and surgical intervention is often required to cope with complications. ​​

Calypso Biotech intends to develop a first-in-class drug, which will not only attenuate intestinal inflammation, but also will circumscribe the manifestation of complications.

IL-15 and Refractory Celiac Disease

There is a clear need for an effective and safe drug for Refractory Celiac Disease (RCD), a dreadful form of small intestine inflammatory disease non-responsive to gluten-free diet.

Calypso Biotech and its collaborative network have identified a factor that plays an important role in the pathology of RCD and will develop a proprietary first-in-class therapeutic antibody against this target.